Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Clear-Cell Renal Cell Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT07160335
What this trial is testing

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

Who this might be right for
Non-small Cell Lung CancerMelanomaRenal Cell Carcinoma
Shanghai Henlius Biotech 174
Not applicableEnded earlyNCT04341740
What this trial is testing

Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma

Who this might be right for
Renal Cell CarcinomaUrothelial Carcinoma
University of Oklahoma 6
Testing effectiveness (Phase 2)Ended earlyNCT03435640
What this trial is testing

REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies

Who this might be right for
MelanomaMerkel Cell CarcinomaTriple Negative Breast Cancer+4 more
Nektar Therapeutics 64
Testing effectiveness (Phase 2)Looking for participantsNCT07611825
What this trial is testing

Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma

Who this might be right for
Advanced RCC
Jinling Hospital, China 33
Very early researchLooking for participantsNCT05733715
What this trial is testing

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma
Abramson Cancer Center at Penn Medicine 30
Testing effectiveness (Phase 2)UnknownNCT00301990
What this trial is testing

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Who this might be right for
Kidney Cancer
Jonsson Comprehensive Cancer Center 65
Testing effectiveness (Phase 2)Active Not RecruitingNCT05672459
What this trial is testing

A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors

Who this might be right for
Solid Tumor
M.D. Anderson Cancer Center 31
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07578025
What this trial is testing

Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

Who this might be right for
Metastatic Clear Cell Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v8
City of Hope Medical Center 34
Testing effectiveness (Phase 2)Ended earlyNCT01925118
What this trial is testing

Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2

Who this might be right for
Metastatic Malignant Melanoma and Renal Cell Carcinoma
Seoul National University Hospital 9
Testing effectiveness (Phase 2)UnknownNCT02429440
What this trial is testing

Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides

Who this might be right for
Renal Cell CancerAdvanced Renal Cell Cancer
University Hospital Tuebingen 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT03634540
What this trial is testing

A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

Who this might be right for
Renal Cell Carcinoma (RCC)Clear Cell Renal Cell Carcinoma (ccRCC)Kidney Cancer+6 more
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 118
Testing effectiveness (Phase 2)Active Not RecruitingNCT06584435
What this trial is testing

Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer

Who this might be right for
High-risk Renal Cell Carcinoma
Tianjin Medical University Second Hospital 100
Testing effectiveness (Phase 2)Ended earlyNCT02771626
What this trial is testing

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Clear Cell Renal Cell Carcinoma (ccRCC)MelanomaNon-small Cell Lung Cancer (NSCLC)
Calithera Biosciences, Inc 118
Not applicableStudy completedNCT03052504
What this trial is testing

Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy

Who this might be right for
Bladder CancerRenal Cell Carcinoma
Jørgen Bjerggaard Jensen 156
Not applicableLooking for participantsNCT07461090
What this trial is testing

Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost Analysis

Who this might be right for
Nonfunctioning KidneyRenal Cell Carcinoma (RCC)
Menoufia University 60
Testing effectiveness (Phase 2)UnknownNCT05879510
What this trial is testing

68Ga-NY104 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses

Who this might be right for
Clear Cell Renal Cell Carcinoma
Peking Union Medical College Hospital 63
Testing effectiveness (Phase 2)Ended earlyNCT00480935
What this trial is testing

Neoadjuvant Sutent for Patients With Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma
University Health Network, Toronto 3
Not applicableUnknownNCT01141816
What this trial is testing

Contrast-enhanced Ultrasound for Follow-up After Radiofrequency Ablation of Kidney Lesions

Who this might be right for
Carcinoma, Renal Cell
St. Joseph's Healthcare Hamilton 30
Very early researchEnded earlyNCT02885649
What this trial is testing

Enzalutamide Before Surgery in Treating Patients With Kidney Cancer

Who this might be right for
Clear Cell Renal Cell CarcinomaStage I Renal Cell Cancer
Rutgers, The State University of New Jersey 3
Early research (Phase 1)Ended earlyNCT05121948
What this trial is testing

HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

Who this might be right for
Squamous Cell Carcinoma of Head and NeckColo-rectal CancerNon Small Cell Lung Cancer+3 more
HiberCell, Inc. 35
Next Page